Fairmount Funds Management
$1.5B 13F equity value
13 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Fairmount Funds Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ORKA | ORUKA THERAPEUTICS INC | 3,705,262 | $353M | 23.3% |
| DNTH | DIANTHUS THERAPEUTICS INC | 2,537,191 | $247M | 16.3% |
| DMRA | DAMORA THERAPEUTICS INC | 8,713,000 | $227M | 15.0% |
| COGT | COGENT BIOSCIENCES INC | 5,503,418 | $213M | 14.1% |
| JBIO | JADE BIOSCIENCES INC | 4,553,494 | $101M | 6.7% |
| ELVN | ENLIVEN THERAPEUTICS INC | 1,855,644 | $94M | 6.2% |
| VRDN | VIRIDIAN THERAPEUTICS INC | 5,090,928 | $94M | 6.2% |
| ZBIO | ZENAS BIOPHARMA INC | 2,359,025 | $60M | 4.0% |
| CBIO | CRESCENT BIOPHARMA INC. | 2,747,866 | $49M | 3.3% |
| APGE | APOGEE THERAPEUTICS INC | 298,647 | $40M | 2.6% |
Track Fairmount Funds Management's 13F portfolio: $1.5B in reported holdings, 13 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}